Financings in Brief: Aastrom Biosciences
This article was originally published in The Gray Sheet
Executive Summary
Aastrom Biosciences: Company plans a secondary offering of 1.5 mil. shares of common stock. Net proceeds will help fund clinical trials of Aastrom's cell production system, designed for use in large scale ex vivo production of a variety of therapeutic cells ("The Gray Sheet" May 26, I&W-11), as well as R&D of other product candidates, and provide working capital. Cowen & Company is managing the deal...